论文信息 - Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome - 字舞流文

Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

B. Fox | J. Dipersio | J. Wigginton | S. Paolini | G. Martinelli | C. Bifulco | H. Lelièvre | N. Vey | B. Löwenberg | D. Rizzieri | K. Jacobs | F. Ciceri | M. Arellano | G. Huls | G. Uy | C. Ballesteros-Merino | M. Carrabba | E. Bonvini | J. Davidson-Moncada | D. Li | Ross La Motte-Mohs | Jichao Sun | M. Rettig | M. Topp | J. Godwin | J. Baughman | M. Foster | Kathy M. Tran | M. Shannon | Karen Spohn | N. Lonsdale | K. Tran | Daner Li